| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/28/2004 | EP1143946B1 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 01/28/2004 | EP1061944B1 Therapeutic chemokine receptor antagonists |
| 01/28/2004 | EP0968291B1 Antibody fragment-polymer conjugates |
| 01/28/2004 | EP0914345B1 Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2) |
| 01/28/2004 | EP0841927B1 Quinolones and their therapeutic use |
| 01/28/2004 | EP0839028B1 Solid dispersions of rapamycin |
| 01/28/2004 | CN1471583A Packaging of positive-strand RNA virus replicon particles |
| 01/28/2004 | CN1471579A CRIPTO tumour polypeptide |
| 01/28/2004 | CN1471575A Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells |
| 01/28/2004 | CN1471539A Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
| 01/28/2004 | CN1471536A Chemokine receptor antagonsis and method of use thereof |
| 01/28/2004 | CN1471534A 桥(连)哌嗪衍生物 Bridge (even) piperazine derivatives |
| 01/28/2004 | CN1471528A Pyrrolidine derivatives and their use as chymase inhibitor |
| 01/28/2004 | CN1471515A Compounds effective as beta-2-adrenoreceptor agonists as well as PDE-4-inhibitors |
| 01/28/2004 | CN1471511A Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 01/28/2004 | CN1471387A Oral dosage self-emulsifying formulations of pyranone proteinase inhibitors |
| 01/28/2004 | CN1470240A Controllable release system of glucocorticoid and its preparation and use |
| 01/28/2004 | CN1136212C Thiophene nitrone compounds |
| 01/28/2004 | CN1136203C Benzoxazine and penzothiazine derivatives and their use in pharmaceuticals |
| 01/28/2004 | CN1136189C Substituted heterocyclic compounds, preparing method thereof and pharmaceutical composition containig them |
| 01/28/2004 | CN1136187C 1-amino-alkylcyclohexane NMDA receptor antagonists |
| 01/28/2004 | CN1135983C Application of diacid (5-androstene-17-one-3 beta-hydroxy) diester in preparing medicine |
| 01/27/2004 | US6683183 Bicyclic heterocycles that inhibit cyclin-dependent kinase or tyrosine kinase enzymes, or both, for treatment of proliferative disorders |
| 01/27/2004 | US6683103 Sulfonamides containing oxazole and substituted thiophene rings, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure |
| 01/27/2004 | US6683096 Indolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 01/27/2004 | US6683093 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease |
| 01/27/2004 | US6683088 Sulfonamido ether substituted imidazoquinolines |
| 01/27/2004 | US6683078 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/27/2004 | US6683074 Cyclic amine derivatives-CCR-3 receptor antagonists |
| 01/27/2004 | US6683055 Guanidine or amidine termined peptides |
| 01/27/2004 | US6683054 Use of melagatran |
| 01/27/2004 | US6683052 Lipopeptides containing an interferon-γ fragment, and uses thereof in pharmaceutical compositions |
| 01/27/2004 | US6682928 Cell is transformed to express on its surface a component which binds to an fc receptor of an effector cell used as a vehicle to increase an cell lysis and phagocytosis against an antigen associated with the cell |
| 01/27/2004 | US6682906 Cloned glutamic acid decarboxylase |
| 01/27/2004 | US6682735 Anti-IgE antibodies |
| 01/27/2004 | CA2281927C Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase |
| 01/27/2004 | CA2214720C Arylsulfonylamino hydroxamic acid derivatives |
| 01/27/2004 | CA2050569C Diphenyl compounds which inhibit arachidonic acid metabolism, and their use in pharmaceutical compositions |
| 01/27/2004 | CA2002607C Natural killer stimulatory factor |
| 01/22/2004 | WO2004007735A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 01/22/2004 | WO2004007709A2 Production of polyketides |
| 01/22/2004 | WO2004007701A1 Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| 01/22/2004 | WO2004007517A1 Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof |
| 01/22/2004 | WO2004007515A1 Sulfotransferase inhibitors |
| 01/22/2004 | WO2004007511A1 Mangostine extract |
| 01/22/2004 | WO2004007494A1 Phenylalanine enamide derivatives |
| 01/22/2004 | WO2004007491A1 Azolidinone-vinyl fused-benzene derivatives |
| 01/22/2004 | WO2004007481A2 Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
| 01/22/2004 | WO2004007480A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 01/22/2004 | WO2004007479A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 01/22/2004 | WO2004007478A2 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 01/22/2004 | WO2004007472A1 Ccr4 antagonist and medicinal use thereof |
| 01/22/2004 | WO2004007464A1 Imidazole derivative |
| 01/22/2004 | WO2004007457A2 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | WO2004007437A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 01/22/2004 | WO2004007423A1 Novel salt forms of poorly soluble probucol esters and ethers |
| 01/22/2004 | WO2004006951A1 Reagents and methods for engaging unique clonotypic lymphocyte receptors |
| 01/22/2004 | WO2004006950A2 Use of cd152 for treating autoimmune diseases and inflammations |
| 01/22/2004 | WO2004006927A2 Sulphonylpiperidine derivatives containing an alkenyl or alkynly moiety for use as matrix metalloproteinase inhibitors |
| 01/22/2004 | WO2004006926A1 Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors |
| 01/22/2004 | WO2004006925A1 N-sulfonylpiperidines as metalloproteinase inhibitors (tace) |
| 01/22/2004 | WO2004006920A1 Topical treatment of skin diseases |
| 01/22/2004 | WO2004006918A1 Phenylalanine enamide derivatives containing a spiro`3.5!non-1-ene ring for use as integrin inhibitors |
| 01/22/2004 | WO2004006865A2 Compounds, compositions, and methods |
| 01/22/2004 | WO2004006853A2 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | WO2004006847A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 01/22/2004 | WO2004006662A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARα GENE TRANSFERRED THEREINTO AND USE THEREOF |
| 01/22/2004 | WO2003082813A3 Improvements in pharmaceutical compositions |
| 01/22/2004 | WO2003078595A3 Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response |
| 01/22/2004 | WO2003074569A3 Bispecific antibody point mutations for enhancing rate of clearance |
| 01/22/2004 | WO2003064439A3 Sialic carbohydrates |
| 01/22/2004 | WO2003064383A3 Phosphorus-containing compounds & uses thereof |
| 01/22/2004 | WO2003060521A3 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 01/22/2004 | WO2003059380A3 Oral vaccination |
| 01/22/2004 | WO2003055462A3 Composition comprising at least an alkanolamide for inhibiting langerhans cell migration, and uses thereof |
| 01/22/2004 | WO2003055447A3 Heterocyclic acridone inhibitors of impdh enzyme |
| 01/22/2004 | WO2003048205A3 Novel proteins with il-6 inhibiting activity |
| 01/22/2004 | WO2003045316A3 Polynucleotide therapy |
| 01/22/2004 | WO2003025121A3 Igf-binding protein-derived peptide or small molecule |
| 01/22/2004 | WO2003024395A8 Linked biaryl compounds |
| 01/22/2004 | WO2003024390A3 Hydroxyeicosenoic acid analogs |
| 01/22/2004 | WO2003020889A3 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 01/22/2004 | WO2002092573A3 Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| 01/22/2004 | WO2002078643A3 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 01/22/2004 | WO2002069886A3 Modified proteins, designer toxins, and methods of making thereof |
| 01/22/2004 | US20040014976 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
| 01/22/2004 | US20040014973 Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines |
| 01/22/2004 | US20040014956 For increasing nuclease resistance of antisense sequences |
| 01/22/2004 | US20040014809 Novel n-( 2-phenyl-3-aminopropyl)naphtamides |
| 01/22/2004 | US20040014802 Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof |
| 01/22/2004 | US20040014796 Antiinflammatory agents; rheumatic diseases; antitumor agents |
| 01/22/2004 | US20040014793 Stability in blood |
| 01/22/2004 | US20040014787 Hormone inhibitors; controlling fertility |
| 01/22/2004 | US20040014783 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders |
| 01/22/2004 | US20040014782 Combination therapy for the treatment of diseases involving inflammatory components |
| 01/22/2004 | US20040014779 Testing for immunology response moderators; viricides, antitumor agents |
| 01/22/2004 | US20040014778 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 01/22/2004 | US20040014776 Anticancer agents; cyclin-dependent kinase inhibitor |
| 01/22/2004 | US20040014763 beta-sheet mimetics and composition and methods relating thereto |
| 01/22/2004 | US20040014760 4- (2-butylamino) -2, 7-dimethyl-8- (2-methyl-6-methoxypyrid-3-YL) pyrazolo- [1,5-A] -1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |